Anacor Pharmaceuticals Inc. has enrolled the first patient in a pair of pivotal phase III trials of AN2728, its lead topical anti-inflammatory candidate for the treatment of atopic dermatitis and psoriasis that could eventually offer a new alternative to corticosteroids and topical immunomodulator therapies for the common skin conditions.